Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered t cells take on lung cancer in early trial

NCT ID NCT02592577

Disease control Sponsor: Adaptimmune Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new treatment for people with advanced non-small cell lung cancer that had grown after standard therapy. Researchers took patients' own immune cells, genetically modified them to recognize and attack cancer cells, and infused them back after chemotherapy. The main goal was to check safety and find the right dose, with 28 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
genetically modified T cells (MAGE A10ᶜ⁷⁹⁶T)
What this could lead to
If it works, this could point toward a new treatment option for advanced lung cancer that has not responded to other therapies.
What could go wrong
This is an early phase 1 trial with only 28 participants, so it is too small to prove effectiveness. The treatment involves strong chemotherapy and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

28 people

The number who actually took part.

Started

Nov 2015

Finished

Mar 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease 2. Subject has received at least one line of prior therapy 3. Subjects with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively. Subject may have received PD-1 or PDL-1 inhibitors and or chemotherapy. There is no limit on lines of prior anti-cancer therapy (a washout period applies for recent anti-cancer treatments). 4. Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion. 5. Subject is HLA-A\*02:01 or HLA-A\*02:06 positive. 6. Subject's tumor (either an archival specimen or a fresh biopsy if archival tissue is unavailable) has been pathologically reviewed by a designated central laboratory confirming MAGE-A10 expression. 7. Subject has an ECOG Performance Status 0-1 and anticipated life expectancy \>6 months prior to apheresis and \>3 months prior to lymphodepletion. 8. Subject is ≥18 to ≤75 years of age 9. Adequate organ function Key Exclusion Criteria: 1. Subject is HLA-A\*02:05, HLA-B\*15:01 and/or HLA-B\*46:01 positive. 2. History of chronic or recurrent (within the last year prior to enrollment) severe autoimmune or active immune-mediated disease requiring steroids or other immunosuppressive treatments. 3. Subject has symptomatic CNS metastases. Subjects with prior history of symptomatic CNS metastasis must have received treatment and be neurologically stable for at least 1 month prior to leukapheresis and lymphodepletion. 4. Active malignancy besides NSCLC within 3 years prior to screening. 5. Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection; * Clinically significant cardiac disease * Inadequate pulmonary function * Interstitial lung disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma Non-small cell lung cancer

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Duke University Medical Center, Duke Cancer Institute

    Durham, North Carolina, 27710, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Hospital Universitario 12 Octubre Avda. de Córdoba s/n

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, 28040, Spain

  • Indiana University Simon Cancer Center

    Indianapolis, Indiana, 46033, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G1X6, Canada

  • Stanford Cancer Center

    Palo Alto, California, 94304, United States

  • Tennessee Oncology- Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University College Hospital Macmillan Cancer Centre

    London, WC1E 6AG, United Kingdom

  • University of Maryland, Greenebaum Cancer Center

    Baltimore, Maryland, 21157, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • Washington University, School of Medicine

    St Louis, Missouri, 63110, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.